妊娠合并系统性红斑狼疮患者应用DNA免疫吸附治疗后的妊娠结局

目的 探讨DNA免疫吸附治疗用于妊娠合并系统性红斑狼疮（SLE）患者的临床效果。方法 对69例妊娠合并SLE患者随机进行免疫吸附治疗35例（治疗组）和常规治疗34例（对照组）。将治疗组的动脉血流经DNA免疫吸附剂（罐）,然后由静脉回输至体内。比较两组的妊娠结局和并发症发生情况。结果 妊娠并发症妊娠高血压综合征（妊高征）、胎盘功能不全、流产等]发生率：治疗组为28．6％、对照组为85．3％,两组比较,差异有极显著性（P＜0．01）;胎儿丢失率：治疗组为20．0％、对照组为58．8％,两组比较,差异有极显著性（P＜0．01）。早产儿发生率：治疗组为8．6％、对照组为26．5％,两组比较,差异有显著性（P＜0．05）。结论 DNA免疫吸附治疗妊娠合并SLE,临床效果优于常规治疗。

Outcome of pregnancy with systemic lupus erythematosus treated with DNA immunoabsorbent

OBJECTIVE: To study the outcome of pregnancy with systemic lupus erythematosus (SLE) treated by DNA immunoabsorbent therapy. METHODS: Sixty nine SLE women with pregnancy were randomly enrolled into DNA immunoabsorbent group (35, group I) and common therapeutic group (34, group II) as control. Outcomes of pregnancy and complications were analyzed. RESULTS: The incidence of complication and fetus loss in group I was 28.6% (10 cases) and 20.0% (7 cases), while 85.3% (29 cases) and 58.8% (20 cases) in group II, there was very significant difference respectively (P < 0.01). The incidence of premature birth was 8.6% (3 cases) in group I, 26.5% (9 cases) in group II, the difference was significant (P < 0.05). CONCLUSION: DNA immunoabsorbent was more efficient than common therapy in the management of SLE with pregnancy.